id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-P-0247-0007,FDA,FDA-2007-P-0247,"Citizen Petition from Regulus Pharmaceutical Consulting, Inc.",Other,CP-Citizen Petition,2008-05-15T04:00:00Z,2008,5,2008-05-15T04:00:00Z,,2025-03-04T22:13:03Z,,0,0,090000648042b10f
FDA-2007-P-0247-0006,FDA,FDA-2007-P-0247,"Letter from FDA CDER to Regulus Pharmaceutical Consulting, Inc",Other,Letter(s),2007-11-30T05:00:00Z,2007,11,,,2025-03-04T22:09:52Z,,0,0,090000648042b114
FDA-2007-P-0247-0005,FDA,FDA-2007-P-0247,"Determination That ELOXATIN (Oxaliplatin for Injection), 50 and 100 Milligrams Per Vial, Sterile Lyophilized Powder for Injection, Was Not Withdrawn From Saie for Reasons of Safety or Effectiveness",Notice,N-Notice,2007-11-27T05:00:00Z,2007,11,2007-11-26T05:00:00Z,,2025-03-05T16:57:42Z,E7-22973,0,0,090000648042b113
FDA-2007-P-0247-0004,FDA,FDA-2007-P-0247,Correction - Acknowledgement Letter from FDA/DMB to Regulus Pharmaceutical Consulting,Other,Correction(s),2007-03-01T05:00:00Z,2007,3,,,2025-03-04T22:01:41Z,,0,0,090000648042b112
FDA-2007-P-0247-0003,FDA,FDA-2007-P-0247,Correction - Acknowledgement Letter from FDA/DMB to Regulus Pharmaceutical Consulting,Other,Correction(s),2007-03-01T05:00:00Z,2007,3,,,2025-03-04T22:03:02Z,,0,0,090000648042b111
FDA-2007-P-0247-0001,FDA,FDA-2007-P-0247,"Acknowledgement Letter from FDA/DMB to Regulus Pharmaceutical Consulting, Inc.",Other,Acknowledgement Letter/Receipt,2007-02-22T05:00:00Z,2007,2,,,2025-03-04T21:52:49Z,,0,0,090000648042b10b
FDA-2007-P-0247-0002,FDA,FDA-2007-P-0247,"Acknowledgement Letter from FDA/DMB to Regulus Pharmaceutical Consulting, Inc.",Other,Acknowledgement Letter/Receipt,2007-02-22T05:00:00Z,2007,2,,,2025-03-04T21:54:44Z,,0,0,090000648042b110